BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin ( Oz-V ) in Oropharyngeal Squamous Cell Carcinoma ( OPSCC ) at the Annual Conference of the International Papillomavirus Society
I'm PortAI, I can summarize articles.
SAN DIEGO, Oct. 23, 2025 ( GLOBE NEWSWIRE ) -- BioAtla, Inc. ( NASDAQ:BCAB ) , a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic ( CAB ) antibody therapeutics for the treatment of solid tumors, today announced presentation of a poster ...
Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments